87 related articles for article (PubMed ID: 36598346)
1. Analysis of Antigen-Specific T and B Cells for Monitoring Immune Protection Against SARS-CoV-2.
De Biasi S; Paolini A; Lo Tartaro D; Gibellini L; Cossarizza A
Curr Protoc; 2023 Jan; 3(1):e636. PubMed ID: 36598346
[TBL] [Abstract][Full Text] [Related]
2. Immune Response to SARS-CoV-2 Vaccine in 2 Men.
Gupta S; Su H; Agrawal S
Int Arch Allergy Immunol; 2022; 183(3):350-359. PubMed ID: 34794147
[TBL] [Abstract][Full Text] [Related]
3. Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response.
Pušnik J; König J; Mai K; Richter E; Zorn J; Proksch H; Schulte B; Alter G; Streeck H
J Virol; 2022 Aug; 96(15):e0076022. PubMed ID: 35862718
[TBL] [Abstract][Full Text] [Related]
4. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
[TBL] [Abstract][Full Text] [Related]
7. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination.
Newell KL; Waldran MJ; Thomas SJ; Endy TP; Waickman AT
Cytometry A; 2022 Jun; 101(6):474-482. PubMed ID: 35468250
[TBL] [Abstract][Full Text] [Related]
10. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
[TBL] [Abstract][Full Text] [Related]
11. Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2.
Pettini E; Medaglini D; Ciabattini A
Front Immunol; 2022; 13():1058748. PubMed ID: 36505416
[TBL] [Abstract][Full Text] [Related]
12. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents.
Torres I; Albert E; Giménez E; Alcaraz MJ; Botija P; Amat P; Remigia MJ; Beltrán MJ; Rodado C; Huntley D; Olea B; Navarro D
Clin Microbiol Infect; 2021 Nov; 27(11):1672-1677. PubMed ID: 34174397
[TBL] [Abstract][Full Text] [Related]
13. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens.
Vojdani A; Vojdani E; Melgar AL; Redd J
Front Immunol; 2022; 13():1003094. PubMed ID: 36211404
[TBL] [Abstract][Full Text] [Related]
14. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination.
Vespa S; Simeone P; Catitti G; Buca D; De Bellis D; Pierdomenico L; Pieragostino D; Cicalini I; Del Boccio P; Natale L; Owens T; Khorooshi R; De Laurenzi V; Stuppia L; Lanuti P
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012246
[TBL] [Abstract][Full Text] [Related]
18. Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.
White AD; Sibley L; Sarfas C; Morrison AL; Bewley K; Churchward C; Fotheringham S; Gkolfinos K; Gooch K; Handley A; Humphries HE; Hunter L; Kennard C; Longet S; Mabbutt A; Moffatt M; Rayner E; Tipton T; Watson R; Hall Y; Bodman-Smith M; Gleeson F; Dennis M; Salguero FJ; Carroll M; McShane H; Cookson W; Hopkin J; Sharpe S
Front Immunol; 2021; 12():801799. PubMed ID: 35222355
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
20. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
